All In MedTech

Device Trial Radar · NCT04904653

The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage

Randomized Controlled and Single Blind Clinical Trial in Women With Breast Cancer and Axillary Lymphadenectomy, to Evaluate the Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage

Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

118

Planned (sponsor's estimate)

Start

Nov 8, 2021

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Instituto de Investigación Hospital Universitario La PazAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Asociación De Cirujanos De Mama De Toledo
First posted
May 27, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hemopatch is an alternative to reduce morbidity associated with axillary lymphadenectomy surgery, possibly contributing to improved patient management, clinical outcomes, and hospital costs. We propose a multicenter, controlled, and randomized trial to study the efficacy of Hemopatch in reducing serous wound drainage.

Conditions

  • Hemopatch
  • Breast Cancer
  • Axillary Lymphadenectomy

Interventions

  • HemopatchDevice

    HEMOPATCH Sealing Hemostat ("HEMOPATCH") consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant. HEMOPATCH is supplied in the following 3 sizes: * HEMOPATCH 27 x 27 mm * HEMOPATCH 45 x 45 mm * HEMOPATCH 45 x 90 mm

  • Control groupOther

    No sealant (liquid, gel or patch) + suction drain

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total volume in milliliters (ml) of drainageTime frame: In the last 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • General Surgery and Digestive System Service

    Toledo, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.